Want to see HK:0897 full AI Analyst Report?
Wai Yuen Tong Medicine Holdings Limited (0897) Stock Price & Analysis
0897 Stock Chart & Stats
- Day’s Range
- HKD 0.35 - HKD 0.39
- 52-Week Range
- HKD 0.27 - HKD 0.49
- Previous Close
- HKD 0.34
- Volume
- 490.00K
- Average Volume (3M)
- 512.27K
- Market Cap
- HKD 401.18M
- Enterprise Value
- HKD 560.58M
- Total Cash (Recent Filing)
- HKD 147.44M
- Total Debt (Recent Filing)
- HKD 279.29M
- Price to Earnings (P/E)
- 100.0
- Beta
- 0.70
- Next Earnings
- Dec 01, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Aug 22, 2024
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Deleveraging
The sharp reduction in debt materially lowers financial risk and interest-related pressure, giving Wai Yuen Tong greater flexibility to sustain operations and fund priorities. A much healthier capital structure also improves resilience if revenue remains under pressure over the next several quarters.
Positive Cash Generation
Positive operating and free cash flow show that the business is generating cash despite very thin reported earnings. This provides an internal source for working capital and investment, reduces reliance on external financing, and supports stability after the company’s substantial deleveraging.
Improved Gross Margin
The higher gross margin indicates better product mix or gross-level economics than in 2023, while the return to positive net income marks progress from earlier loss years. If maintained, this improvement can help the retail and distribution model absorb cost pressure and rebuild earnings power.
Bears Say
Revenue Contraction
Persistent revenue contraction points to a weakening scale base for the retail and distribution operations. Lower sales can reduce operating leverage, limit the company’s ability to spread fixed costs, and make it harder for margin improvements to translate into durable profit growth.
Weak Operating Profitability
Very thin net margins leave little buffer against ongoing expenses or weaker trading, while negative operating profit shows that core operations are not yet consistently profitable. This weak earnings quality limits reinvestment capacity and makes future results sensitive to modest cost or sales changes.
Declining Cash Momentum
Although free cash flow remains positive, the sharp year-over-year decline and historical volatility reduce confidence that cash generation is consistently improving. Less dependable cash conversion could constrain investment and capital allocation if revenue weakness or operating pressures persist.
Wai Yuen Tong Medicine Holdings Limited News
0897 FAQ
What was Wai Yuen Tong Medicine Holdings Limited’s price range in the past 12 months?
What is Wai Yuen Tong Medicine Holdings Limited’s market cap?
When is Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date?
How were Wai Yuen Tong Medicine Holdings Limited’s earnings last quarter?
Is Wai Yuen Tong Medicine Holdings Limited overvalued?
Does Wai Yuen Tong Medicine Holdings Limited pay dividends?
What is Wai Yuen Tong Medicine Holdings Limited’s EPS estimate?
How many shares outstanding does Wai Yuen Tong Medicine Holdings Limited have?
What happened to Wai Yuen Tong Medicine Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Wai Yuen Tong Medicine Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Wai Yuen Tong Medicine Holdings Limited Stock Smart Score
Company Description
Wai Yuen Tong Medicine Holdings Limited
Wai Yuen Tong Medicine Holdings Limited operates as an investment holding company with a multifaceted business portfolio. Its core activities encompass the production, processing, and retail distribution of traditional Chinese medicines, Western pharmaceuticals, and a range of health and personal care products. These offerings reach customers across Hong Kong, mainland China, Macau, and international markets. The company's Chinese medicine and health food lines are marketed under the Wai Yuen Tong brand, while its Western pharmaceutical and personal care items are available under the Madame Pearl's and Pearl's labels. Beyond its product-focused segments, the group also engages in property investment, ownership, and sales, provides financial services, and oversees an agricultural produce exchange. Founded in 1897, the company is headquartered in Kowloon Bay, Hong Kong, and operates as a subsidiary of Rich Time Strategy Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kit Man Chan
- Employees
- 691
- Website
- www.wyth.net
- Address
- HK
Wai Yuen Tong Medicine Holdings Limited (0897) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 6 | 4 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 9 | 0 | 3 |






